Down-Regulation of Surface Receptors for TNF and IL-1 on Circulating Monocytes and Granulocytes During Human Endotoxemia: Effect of Neutralization of Endotoxin-Induced TNF Activity by Infusion of a Recombinant Dimeric TNF Receptor

Journal of Immunology

Volumn 158, Issue 3, 1997, Pages 1490-1497

  Van Der Poll, Tom ^a,b   Coyle, Susette M ^a   Kumar, Ashwini ^a   Barbosa, Karen ^a   Agosti, Jan M ^c   Lowry, Stephen F ^a,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c AMGEN INC   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR; LIPOPOLYSACCHARIDE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; DIMERIZATION; DOWN REGULATION; DRUG ANTAGONISM; ENDOTOXEMIA; GRANULOCYTE; HUMAN; MALE; METABOLISM; MONOCYTE; THERMOREGULATION;

ADULT; BODY TEMPERATURE REGULATION; DIMERIZATION; DOWN-REGULATION; ENDOTOXEMIA; GRANULOCYTES; HUMANS; LIPOPOLYSACCHARIDES; MALE; MONOCYTES; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031065237     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Bone, R. C. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115:457.
2. Beutler, B., I. W. Milsark, and A. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869.
3. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662.
4. Ohlsson, K., P. Björk, M. Bergenfeldt, R. Hageman, and R. C. Thompson. 1990. Interleukin 1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550.
5. Fischer, E., M. A. Marano, K. J. van Zee, C. S. Rock, A. S. Hawes, W. A. Thompson, L. DeForge, J. S. Kenney, D. G. Remick, D. C. Bloedow, R. C. Thompson, S. F. Lowry, and L. L. Moldawer. 1992. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J. Clin. Invest. 89:1551.
6. Tartaglia, L. A., and D. V. Goeddel. 1992. Two TNF receptors. Immunol. Today 13:151.
7. Dinarello, C. A. 1993. Modalities for reducing interleukin 1 activity in disease. Immunol. Today 14:260.
8. Sims, J. E., J. G. Giri, and S. K. Dower. 1994. The two interleukin-1 receptors play different roles in IL-1 actions. Clin. Immunol. Immunopathol. 72:9.
9. Tartaglia, L. A., R. F. Weber, I. S. Figari, C. M. A. Reynolds, J. Palladino, and D. V. Goeddel. 1991. Two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA 88:9292.
10. Loetscher, H., D. Stueber, D. Banner, F. Mackay, and W. Lesslauer. 1993. Human tumor necrosis factor α (TNFα) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J. Biol. Chem. 268:26350.
11. Mackay, F., H. Loetscher, D. Stueber, G. Gehr, and W. Lesslauer. 1993. Tumor necrosis factor α (TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J. Exp. Med. 177: 1277.
12. Van Zee, K. J., S. A. Stackpole, W. J. Montegut, M. A. Rogy, S. E. Calvano, K. C. Hsu, M. Chao, C. L. Meschter, H. Loetscher, D. Stüber, U. Ettlin, B. Wipf, W. Lesslauer, S. F. Lowry, and L. L. Moldawer. 1994. A human tumor necrosis factor (TNF) α mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J. Exp. Med. 179:1185.
13. Pfeffer, K., T. Matsuyama, T. M. Kündig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Krönke, and T. W. Mak. 1993. Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457.
14. Rothe, J., W. Lesslauer, H. Lötscher, Y. Lang, P. Koebel, F. Königen, A. Athage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798.
15. Espevik, T., M. Brockhaus, H. Loetscher, U. Nonstad, and R. Shalaby. 1990. Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. J. Exp. Med. 171:415.
16. Tartaglia, L. A., D. Pennica, and D. V. Goeddel. 1993. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J. Biol. Chem. 268:18542.
17. Colotta, F., F. Re, M. Muzio, R. Bertini, N. Polentarutti, M. Sironi, J. Giri, S. K. Dower, J. E. Sims, and A. Mantovani. 1993. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261:472.
18. Sims, J. E., M. A. Gayle, J. L. Slack, M. R. Alderson, T. A. Bird, J. G. Giri, F. Colotta, F. Re, A. Mantovani, K. Shanebeck, K. H. Grabstein, and S. K. Dower. 1993. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc. Natl. Acad. Sci. USA 90:6155.
19. Ding, A. H., E. Sanchez, S. Srimal, and C. Nathan. 1989. Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide. J. Biol. Chem. 264:3924.
20. Porteu, F., and C. Nathan. 1990. Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med. 172:599.
21. Higuchi, M., and B. B. Aggarwal. 1992. Modulation of two forms of tumor necrosis factor receptors and their cellular response by soluble receptors and their monoclonal antibodies. J. Biol. Chem. 267:20892.
22. Winzen, R., D. Wallach, O. Kemper, K. Resch, and H. Holtmann. 1993. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J. Immunol. 150:4346.
23. Porteu, F., and C. Hieblot. 1994. Tumor necrosis factor induces a selective shedding of its p75 receptors from human neutrophils. J. Biol. Chem. 269:2834.
24. Leeuwenberg, J. F. M., T. M. A. A. Jeunhomme, and W. A. Buurman. 1994. Slow release of soluble TNF receptors by monocytes in vitro. J. Immunol. 152:4036.
25. Leeuwenberg, J. F. M., M. A. Dentener, and W. A. Buurman. 1994. Lipopolysaccharide (LPS)-mediated soluble TNF receptor release and TNF receptor expression by monocytes: role of CD14, LPS binding protein, and bactericidal/ permeability increasing protein. J. Immunol. 152:5070.
26. Higuchi, M., and B. B. Aggarwal. 1994. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J. Immunol. 152:3550.
27. Lantz, M., F. Björnberg, I. Olsson, and J. Richter. 1994. Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms. J. Immunol. 152:1362.
28. Joyce, D. A., D. P. Gibbons, P. Green, J. H. Steer, M. Feldmann, and F. M. Brennan. 1994. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on the release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur. J. Immunol. 24:2699.
29. Richter, J., U. Gullberg, and M. Lantz. 1995. TNF-induced superoxide anion production in adherent neutrophils involves both the p55 and p75 TNF receptor. J. Immunol. 154:4142.
30. Van der Poll, T., S. E. Calvano, A. Kumar, C. C. Braxton, S. M. Coyle, K. Barbosa, L. L. Moldawer, and S. F. Lowry. 1995. Endotoxin induces down-regulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood 86:2754.
31. Giri, J. G., J. Wells, S. K. Dower, C. E. McCall, R. N. Guzman, J. Slack, T. A. Bird, K. Shanebeck, K. H. Grabstein, J. E. Sims, and M. R. Alderson. 1994. Elevated levels of shed type II IL-1 receptor in sepsis: potential role for type II receptor in regulation of IL-1 responses. J. Immunol. 153:5802.
32. Colotta, F., S. Orlando, E. J. Fadlon, S. Sozanni, C. Matteucci, and A. Mantovani. 1995. Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells. J. Exp. Med. 181:2181.
33. Spinas, G. A., U. Keller, and M. Brockhaus. 1992. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J. Clin. Invest. 90:533.
34. Van Zee, K. J., T. Kohno, E. Fischer, S. C. Rock, L. L. Moldawer, and S. F. Lowry. 1992. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc. Natl. Acad. Sci. USA 89:4845.
35. Mohler, K. M., D. S. Torrance, C. A. Smith, R. G. Goodwin, K. E. Stremler, V. P. Fung, H. Madani, and M. B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1548.
36. Brockhaus, M., H. J. Schoenfeld, E. J. Schlaeger, W. Hunziker, W. Lesslauer, and H. Loetscher. 1990. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 87: 3127.
37. Digel, W., F. Porzsolt, M. Schmid, F. Herrmann, W. Lesslauer, and M. Brockhaus. 1992. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J. Clin. Invest. 89:1690.
38. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99.
39. Van der Poll, T., A. Marchant, W. A. Buurman, L. Berman, C. V. Keogh, D. D. Lazarus, L. Nguyen, M. Goldman, L. L. Moldawer, and S. F. Lowry. 1995. Endogenous interleukin 10 protects mice from death during septic peritonitis. J. Immunol. 155:5397.
40. Van der Poll, T., S. M. Coyle, K. Barbosa, C. C. Braxton, and S. F. Lowry. 1996. Epinephrine inhibits tumor necrosis factor α and potentiates interleukin 10 production during human endotoxemia. J. Clin. Invest. 97:713.
41. Suffredini, A. F., D. Reda, S. M. Banks, M. Tropea, J. M. Agosti, and R. Miller. 1995. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J. Immunol. 155:5038.
42. Evans, T. J., D. Moyes, A. Carpenter, R. Martin, H. Loetscher, W. Lesslauer, and J. Cohen. 1994. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of Gram-negative sepsis. J. Exp. Med. 180:2173.
43. Jansen, J., T. van der Poll, M. Levi, H. ten Cate, H. Gallati, J. W. ten Cate, and S. J. H. van Deventer. 1995. Inhibition of the release of soluble tumour necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-α antibody. J. Clin. Immunol. 15:45.
44. 2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees. Clin. Exp. Immunol. 100:21.
45. Redl, H., G. Schlag, G. R. Adolf, B. Natmessnig, and J. Davies. 1995. Tumor necrosis factor (TNF)-dependent shedding of the p55 TNF receptor in a baboon model of bacteremia. Infect. Immun. 63:297.
46. Lantz, M., S. Malik, M. Slevin, and I. Olsson. 1990. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2:402.
47. Spriggs, M. K., P. J. Nevens, K. Grabstein, S. K. Dower, D. Cosman, R. J. Armitage, C. J. McMahan, and J. E. Sims. 1992. Molecular characterization of the interleukin-1 receptor (IL-1R) on monocytes and polymorphenuclear cells. Cytokine 4:90.
48. Fong, Y., K. J. Tracey, L. L. Moldawer, D. G. Hesse, K. R. Manogue, J. S. Kenney, A. T. Lee, G. C. Kuo, A. C. Allison, S. F. Lowry, and A. Cerami. 1989. Antibodies to cachetin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170:1627.
49. Van der Poll, T., S. J. H. van Deventer, H. ten Cate, M. Levi, and J. W. ten Cate. 1994. Tumor necrosis factor is involved in the appearance of interleukin 1 receptor antagonist in endotoxemia. J. Infect. Dis. 169:665.